Zenas Biopharma Inc’s recent filing unveils that its Chief Executive Officer MOULDER LEON O JR acquired Company’s shares for reported $0.17 million on Feb 18 ’25. In the deal valued at $6.67 per share,25,000 shares were bought. As a result of this transaction, MOULDER LEON O JR now holds 266,155 shares worth roughly $2.42 million.
Then, Xiao Ting bought 10,000 shares, generating $77,600 in total proceeds. Upon buying the shares at $7.76, the Director now owns 47,000 shares.
Before that, MOULDER LEON O JR bought 45,000 shares. Zenas Biopharma Inc shares valued at $449,100 were divested by the Chief Executive Officer at a price of $9.98 per share. As a result of the transaction, MOULDER LEON O JR now holds 241,155 shares, worth roughly $2.2 million.
Wedbush initiated its Zenas Biopharma Inc [ZBIO] rating to an Outperform in a research note published on March 20, 2025; the price target was $35. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering ZBIO with “Buy” recommendation on December 16, 2024. Rodman & Renshaw started covering the stock on November 05, 2024. It rated ZBIO as “a Buy”.
Price Performance Review of ZBIO
On Tuesday, Zenas Biopharma Inc [NASDAQ:ZBIO] saw its stock fall -2.15% to $9.11. Over the last five days, the stock has gained 15.32%. Zenas Biopharma Inc shares have risen nearly 11.23% since the year began.
Levels Of Support And Resistance For ZBIO Stock
The 24-hour chart illustrates a support level at 8.70, which if violated will result in even more drops to 8.29. On the upside, there is a resistance level at 9.67. A further resistance level may holdings at 10.24. The Relative Strength Index (RSI) on the 14-day chart is 61.36, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.77, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 21.77%. Stochastics %K at 83.56% indicates the stock is a selling.
How much short interest is there in Zenas Biopharma Inc?
A steep rise in short interest was recorded in Zenas Biopharma Inc stocks on 2025-03-14, growing by 0.27 million shares to a total of 3.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 3.47 million shares. There was a rise of 7.18%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 08, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
